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Context: Subclinical thyroid dysfunction is common in older people. However, its clinical impor-
tance is uncertain.
Objective: Our objective was to determine the extent to which subclinical hyperthyroidism and
hypothyroidism influence the risk of heart failure and cardiovascular diseases in older people.
Setting and Design: The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) is an
prospective cohort study.
Patients: Patients included men and women aged 70–82 yr (n  5316) with known cardiovascular
risk factors or previous cardiovascular disease.
Main Outcome Measures: Incidence rate of heart failure hospitalization, atrial fibrillation, and
cardiovascular events and mortality according to baseline thyroid status were evaluated. Euthyroid
participants (TSH 0.45–4.5 mIU/liter) were compared with those with subclinical hyperthyroidism
(TSH 0.45 mIU/liter) and those with subclinical hypothyroidism (TSH 4.5 mIU/liter, both with
normal free T4).
Results: Subclinical hyperthyroidism was present in 71 participants and subclinical hypothyroidism
in 199 participants. Over 3.2 yr follow-up, the rate of heart failure was higher for subclinical
hyperthyroidism compared with euthyroidism [age- and sex-adjusted hazard ratio (HR)  2.93,
95% confidence interval (CI)  1.37–6.24, P  0.005; multivariate-adjusted HR  3.27, 95% CI 
1.52–7.02, P  0.002). Subclinical hypothyroidism (only at threshold 10 mIU/liter) was associated
with heart failure (age- and sex-adjusted HR  3.01, 95% CI  1.12–8.11, P  0.029; multivariate
HR  2.28, 95% CI  0.84–6.23). There were no strong evidence of an association between sub-
clinical thyroid dysfunction and cardiovascular events or mortality, except in those with TSH below
0.1 or over 10 mIU/liter and not taking pravastatin.
Conclusion: Older people at high cardiovascular risk with low or very high TSH along with normal
free T4 appear at increased risk of incident heart failure. (J Clin Endocrinol Metab 97: 852–861,
2012)
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Subclinical thyroid dysfunction is defined as a biochem-ical disorder including an abnormal TSH and normal
free T4 levels (1). The disorder has been proposed as a
possible modifiable risk factor for cardiovascular disease
(CVD) (1–3). Subclinical thyroid dysfunction increases
with age (4). Because the prevalence is high, the cardio-
vascular consequences of thyroid dysfunction might have
a large impact in an aging population, particularly in
adults at high risk or with preexisting CVD (5). However,
in older people, evidence from observational studies is rare
and inconsistent, and therefore clinical relevance remains
uncertain. For instance, subclinical hypothyroidism has
been shown to be inversely related to mortality in the old-
est old (6, 7), although this was not confirmed in a recent
meta-analysis including younger adults (3).
Thyroid hormones have distinct effects on the heart and
peripheral vasculature (8). Because of the significant he-
modynamic changes driven by thyroid hormones, previ-
ous studies have reported altered cardiac function in sub-
clinical thyroid dysfunction (8, 9), but very few have
directly examined clinical cardiac events, such as heart
failure or atrial fibrillation (10, 11).
Therefore, we examined the association between sub-
clinical thyroid dysfunction with adjudicated cardiovas-
cular events in a large prospective study of older people
with cardiovascular risk factors or preexisting CVD, the




Participants were part of the PROSPER trial designed to ex-
amine the benefits of pravastatin vs. placebo in adults aged
70–82 yr old (12). Details of the design, data collection, and
eligibility criteria have been previously described (12, 13).
Briefly, 5804 individuals with a mean age of 75 yr (52% women),
sufficiently mobile to attend visits at their general practitioner’s
office or the study center, were randomized to 40 mg pravastatin
or placebo in The Netherlands, Scotland, and Ireland. Only par-
ticipants with a history of vascular disease, defined as coronary,
cerebral, or peripheral artery disease, or those with known car-
diovascular risk factors, such as smoking, hypertension, or dia-
betes, were enrolled. Participants with congestive heart failure
[New York Heart Association (NYHA) functional class III or IV]
or electrocardiographic evidence of atrial fibrillation were ex-
cluded as well as those with poor cognitive function (Mini Men-
tal State Examination score  24). Adults with overt thyroid
dysfunction (TSH levels 20 mIU/liter with any free T4, or  10
mIU/liter with low free T4 levels) were also excluded. The Med-
ical Ethics Committee of all centers approved the study, and
informed consent was obtained from all participants. The pres-
ent study represents a post hoc analysis (13).
From the original study sample of 5804 individuals, we ex-
cluded eight participants with unavailable TSH measurement at
baseline and 297 with missing free T4 measurement. We further
excluded 146 patients with overt thyroid dysfunction based on
free T4 measurements, six participants taking antithyroid
medication, and 27 participants taking amiodarone, because
of its potential confounding effect because it affects both thy-
roid function and CVD (8). We additionally excluded four
participants with atrial fibrillation at baseline, who in retro-
spect were protocol violators. Hence, the final sample of our
study was 5316 participants for baseline analysis (Supple-
mental Fig. 1, published on The Endocrine Society’s Journals
Online web site at http://jcem.endojournals.org).
Determinants
TSH levels and free T4 were measured at baseline in all par-
ticipants using state-of-the-art immunoassays for TSH (third-
generation assays with functional sensitivity of 0.05 mIU/liter or
less) and for free T4 in respective laboratory centers (Cork, Ire-
land; Glasgow, Scotland; and Leiden, The Netherlands). Inter-
and intraassay coefficients of variation were less than 5% for
both analytes. To account for the differences of laboratory assays
and to avoid the inclusion of participant with overt thyroid dis-
ease, the narrowest free T4 reference range was used (between 12
and 18 pmol/liter). Thus, 105 older adults with free T4 above 18
pmol/liter were excluded for overt hyperthyroidism and 41 with
free T4 values below 12 pmol/liter were excluded for overt hy-
pothyroidism (Supplemental Fig. 1). In stored (80 C) plasma
drawn from participant at 6 months, we repeated measurement
of TSH and free T4 in all available samples stored at a single
center (University of Glasgow), using the same electrochemilu-
minescence immunodetection method on a Roche Elecsys 2010
(Burgess Hill, UK). The limit of detection of TSH was below
0.005 mIU/liter. The limit of detection of free T4 was 0.3 pmol/
liter, with reference ranges of 12–22 pmol/liter.
We categorized patients into three groups according to TSH
levels at study entry. At baseline, subclinical hyperthyroidism
was defined as participants with TSH levels of less than 0.45
mIU/liter and normal free T4 levels (1). Subclinical hypothyroid-
ism was defined as participants with TSH of 4.5 mIU/liter or
greater and normal free T4 levels (1). Participants with TSH
levels of 0.45 or greater but less than 4.5 were considered as
euthyroid. To assess a possible dose-response effect of TSH, we
further classified subclinical hyperthyroidism into two sub-
groups: TSH less than 0.1 mIU/liter and 0.1–0.44 mIU/liter (1).
Subclinical hypothyroidism was further classified into two sub-
groups: TSH 4.5–10 mIU/liter and more than 10 mIU/liter (3). At
6 months, a similar classification was used to identify those with
persistent subclinical hyperthyroidism, persistent euthyroidism
and persistent subclinical hypothyroidism (Supplemental Fig. 1).
Heart failure, atrial fibrillation, and cardiovascular
events and mortality
We examined combined and individual cardiovascular out-
comes, as previously defined (12), including fatal and nonfatal
coronary heart disease, and CVD, defined as fatal and nonfatal
myocardial infarction, stroke, coronary artery bypass graft,
percutaneous transluminal coronary angioplasty, peripheral ar-
terial surgery, or angioplasty. Incident heart failure hospitaliza-
tions were also recorded and all clinical endpoints were adjudi-
cated by an expert committee blinded to randomized study
medication and using predefined criteria (12). Incident heart fail-
ure hospitalizations were adjudicated using a panel of predefined
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criteria including clinical symptoms, chest radiography, labora-
tory measurements, electrocardiograph, echocardiography, and
hospital discharge reports. New-onset atrial fibrillation was di-
agnosed from an annual single-lead electrocardiograph or, if
noted, on 12-lead electrocardiograph or telemetry performed as
part of hospitalization or other clinical care (14). This general
process of screening has been found to be very sensitive for iden-
tifying new cases in the Framingham study (15).
Potential confounders
Diabetes was defined as self-reported diagnosis or use of an-
tidiabetic drugs or was defined as fasting blood glucose of 7.0
mmol/liter or greater or 11.1 mmol/liter or greater when fasting
status was uncertain (16). Smoking was defined as never, cur-
rent, or former. Baseline lipids, creatinine, blood pressure, heart
rate, body mass index (BMI) measurements, education, alcohol
intake, and medication use were assessed as previously reported
(12, 13).
Statistical analyses
Baseline characteristics are reported in three subgroups ac-
cording to thyroid dysfunction, as described above. Two-sample
t tests and 2 tests were used for group comparisons. The asso-
ciation between subclinical thyroid dysfunction and the different
endpoints were examined using age- and sex-adjusted and mul-
tivariate adjusted Cox proportional hazards models, with the
euthyroidism group as the reference group. Events rates per 1000
person-years of follow-up were calculated and compared with
log-rank tests. A Kaplan-Meier curve censored for death was
used to represent the cumulative incidence of heart failure hos-
pitalization. Potential confounders in the multivariate adjusted
models were determined by biological plausibility for all end-
points: age, sex, education, history of CVD, diabetes, BMI,
smoking status, systolic blood pressure, low-density lipoprotein
(LDL) cholesterol, creatinine, use of -blockers, and use of an-
tiarrhythmic drugs. For each traditional cardiovascular risk fac-
tor and for the use of pravastatin and -blockers, stratified anal-
yses were conducted to better assess the presence of interaction
or confounding. To account for potential change in thyroid sta-
tus over time, we analyzed risks among older adults with
persistent subclinical thyroid dysfunction at 6 months, after ex-
clusion of deaths, those lost to follow-up, heart failure hospital-
ization, and atrial fibrillation events occurring during the first 6
months (Supplemental Fig. 1). We also run sensitivity analyses
excluding 161 participants with thyroid replacement therapy to
assess the effect of endogenous subclinical thyroid dysfunction
only (1). Results are reported as hazard ratio (HR), with 95%
confidence intervals (CI). All analyses were conducted using
Stata version 11.0 (Stata Corp., College Station, TX), and P 
0.05 was considered statistically significant.
Results
Baseline characteristics
The mean age of the study population was 75 yr (SD
3.3 yr). Subclinical hyperthyroidism was present in 71
participants (1.3%) at baseline (Table 1). In line with
expectation, more women than men had subclinical hy-
perthyroidism, and they had a lower weight and creat-
inine level than those with normal thyroid function.
Five of them used thyroid hormone. Subclinical hypo-
thyroidism was present in 199 participants (3.7%), and
66% were women. Prevalence of hypertension and LDL
and total cholesterol levels were slightly elevated in the
subclinical hypothyroidism group in comparison with
those who were euthyroid, and nearly 15% used thyroid
replacement therapy.
Incident heart failure hospitalization
During a 3.2-yr follow-up period, the incidence rate of
hospitalization for heart failure was higher in older people
with subclinical hyperthyroidism compared with the eu-
thyroidism group, with 31 vs. 12 events per 1000 person-
years (P  0.01, Fig. 1) and age- and sex-adjusted HR of
2.93 (95% CI  1.37–6.24, P  0.005) (Table 2). This
association persisted after further adjustment for educa-
tion, history of CVD, diabetes, BMI, smoking status, sys-
tolic blood pressure, LDL cholesterol, creatinine, and use
of -blockers and antiarrhythmics (multivariate adjusted
HR  3.27, 95% CI  1.52–7.02, P  0.002). The asso-
ciation with heart failure was present in both subclinical
hyperthyroidism subgroups, but mainly in those with a
suppressed TSH below 0.1 mIU/liter (age- and sex-ad-
justed HR  4.61, 95% CI  1.71–12.47, P  0.003,
Table 2). In additional stratified analysis, the increased
incidence rate of heart failure hospitalization in adults
with subclinical hyperthyroidism did not differ by age,
gender, history of CVD, -blockers use (P for each inter-
action term  0.05, Fig. 2). The incidence rate of heart
failure within the subclinical hyperthyroidism group was
lower in adults using pravastatin (age- and sex-adjusted
HR  2.44, 95% CI  0.77–7.74) than in those using
placebo (multivariate adjusted HR  3.52, 95% CI 
1.29–9.61), but with a nonsignificant P for interaction
term of 0.65 (Fig. 2).
There was no association between subclinical hypothy-
roidism defined with TSH levels equal or above 4.5 mIU/
liter and incident heart failure hospitalization. However,
in adults with TSH levels above 10 mIU/liter, the incident
rate of heart failure was significantly higher in the age- and
sex-adjusted model compared with euthyroid participants
(HR  3.01, 95% CI  1.12–8.11, P  0.029, Table 2).
Incident atrial fibrillation, cardiovascular events,
and mortality
During the 3.2-yr follow-up, 497 (9.4%) had atrial fi-
brillation, 891 (16.8%) had fatal or nonfatal CVD, 585
participants (11.0%) had fatal or nonfatal myocardial in-
farction, and a total of 547 (10.3%) died. There were no
differences in the incidence rate of atrial fibrillation, fatal
or nonfatal coronary, cerebrovascular events, or total
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CVD between the subclinical thyroid dysfunction groups
and the euthyroidism group. In multivariate models, nei-
ther subclinical hyperthyroidism nor subclinical hypothy-
roidism was significantly associated with atrial fibrillation
or cardiovascular-related events. However, when subclin-
ical thyroid dysfunction was examined only in those with-
out pravastatin, elevated TSH levels above 10 mIU/liter
compared with euthyroidism were associated with an in-
creased risk of cardiovascular events (age- and sex-ad-
justed HR  2.15, 95% CI  1.02–4.54, P  0.044;
multivariate adjusted HR  2.03, 95% CI  0.96–4.32,
P  0.064) and a nonsignificant increased cardiovascular
mortality (age- and sex-adjusted HR  2.14, 95% CI 
0.53–8.67).
Total and cardiovascular mortality rates were similar
between the subclinical hyperthyroidism group, the eu-













TSH (mIU/liter) 0.18 (0.13)a 1.95 (0.90) 7.84 (3.75)a
Free T4 (pmol/liter) 16.0 (1.4) 14.9 (1.6)
Demographics
Age (yr) 75.3 (3.1) 75.3 (3.4) 75.5 (3.2)
Female n (%) 54 (76.1)a 2497 (49.5) 132 (66.3)a
Education (yr) 15.2 (2.1) 15.1 (2.0) 15.0 (2.1)
Country n (%)
Scotland 22 (31.0) 2186 (43.3) 25 (12.6)
Ireland 22 (31.0) 1912 (37.9) 96 (48.2)
The Netherlands 27 (38.3) 948 (18.8) 78 (39.2)
Smoking status n (%)
Never 25 (35.2) 1673 (33.2) 83 (41.7)
Former 33 (46.5) 1985 (39.3) 71 (35.7)
Current 13 (18.3) 1388 (27.5) 45 (22.6)
Alcohol consumption (drinks/wk) 2.7 (5.6)a 5.4 (9.5) 4.4 (8.7)
Comorbidities
Hypertension n (%) 41 (57.8) 3093 (61.3) 138 (69.3)a
Diabetes n (%) 10 (14.8) 534 (10.6) 28 (14.1)
History of vascular disease n (%)b 30 (42.3) 2231 (44.2) 88 (44.2)
Objective measures
Systolic blood pressure (mm Hg) 151.6 (20.9) 154.6 (21.9) 155.9 (22.0)
Diastolic blood pressure (mm Hg) 81.9 (11.3) 83.8 (11.5) 84.5 (11.1)
Heart rate (beat/min)c 65.6 (10.9) 66.3 (11.7) 65.7 (11.1)
Weight (kg) 69.1 (13.5)a 73.5 (13.2) 74.1 (13.7)
Height (cm) 162.9 (8.7)a 165.5 (9.5) 164.3 (8.4)
BMI (kg/m2) 26.0 (4.4) 26.8 (4.1) 27.4 (4.5)
Total cholesterol (mmol/liter) 5.9 (0.9) 5.7 (0.9) 5.9 (0.9)a
LDL cholesterol (mmol/liter) 3.9 (0.8) 3.8 (0.8) 3.9 (0.8)a
HDL cholesterol (mmol/liter) 1.3 (0.4) 1.3 (0.3) 1.3 (0.4)
Triglycerides (mmol/liter) 1.6 (0.7) 1.5 (0.7) 1.6 (0.7)
Fasting glucose (mmol/liter)d 5.6 (1.8) 5.4 (1.4) 5.5 (1.7)
Creatinine (mol/liter) 94.2 (17.5)a 101.1 (22.3) 97.7 (21.9)a
Medication use
Thyroid hormone n (%) 5 (7.0)a 122 (2.4) 34 (17.1)a
Pravastatin n (%) 35 (49.3) 2530 (50.1) 95 (47.7)
Aspirin n (%) 24 (33.8) 1831 (36.3) 71 (35.7)
-Blockers n (%) 17 (23.9) 1312 (26.0) 48 (24.1)
Antiarrhythmics n (%)e 1 (1.4) 111 (2.2) 5 (2.5)
Data are given as mean (SD) unless otherwise indicated. HDL, High-density lipoprotein.
a P  0.05 for comparison with the euthyroidism group.
b Vascular disease defined as history of coronary, cerebral, or peripheral vascular disease.
c Heart rate was available for 5204 participants (two missing in the subclinical hyperthyroidism group and seven missing in the subclinical
hypothyroidism group).
d Fasting glucose was available for 5146 participants (three missing in the subclinical hyperthyroidism group and three missing in the subclinical
hypothyroidism group).
e Other than amiodarone, because participants taking amiodarone were excluded from this study population.
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thyroidism group, and the subclinical hypothyroidism
group. In those with suppressed TSH levels below 0.1
mIU/liter, total and cardiovascular mortality estimates
were above two in comparison with the euthyroidism
group, but none of them reached sta-
tistical significance (Table 3). How-
ever, when subclinical hyperthyroidism
was examined only in those without
pravastatin, suppressed TSH levels be-
low 0.1 mIU/liter were associated with
significantly higher cardiovascular mor-
tality (age- and sex-adjusted HR 
4.78, 95% CI  1.17–19.5, P  0.029;
multivariate adjusted HR  4.87, 95%
CI  1.18–20.0, P  0.028) and higher
total mortality (age- and sex-adjusted
HR  3.13, 95% CI  1.00–9.83, P 
0.05; multivariate adjusted HR  3.14,




Among the 71 participants with sub-
clinical hyperthyroidism at baseline,
two (3%) developed overt hyperthy-
roidism and 10 (14%) normalized both TSH and free T4
at 6 months. Among the 199 participants with subclinical
hypothyroidism at baseline, two died from CVD, one died
FIG. 1. Cumulative incidence of heart failure hospitalization, with respect to subclinical
thyroid dysfunction. P values were based on log-rank tests for survival functions compared
with the euthyroidism group.




























No. of events 4 3 7 194 6 2 4
Incidence rateb 45.7a 21.6 30.9a 12.1 9.7 4.0 32.9a
Age- and sex-adjusted HR (95% CI) 4.61a (1.71–12.47) 1.97 (0.63–6.17) 2.93a (1.37–6.24) 1.00 0.87 (0.38–1.96) 0.36 (0.09–1.44) 3.01a (1.12–8.11)
Multivariate adjusted HR (95% CI)c 4.78a (1.76–13.04) 2.29 (0.73–7.20) 3.27a (1.52–7.02) 1.00 0.80 (0.36–1.82) 0.35 (0.09–1.42) 2.28 (0.84–6.23)
Atrial fibrillation
No. of events 1 2 3 478 16 11 5
Incidence rateb 11.6 14.2 13.2 30.5 26.1 22.3 41.0
Age- and sex-adjusted HR (95% CI) 0.46 (0.64–3.25) 0.51 (0.13–2.05) 0.49 (0.16–1.53) 1.00 0.93 (0.57–1.54) 0.80 (0.44–1.46) 1.47 (0.61–3.55)
Multivariate adjusted HR (95% CI)c 0.50 (0.07–3.55) 0.55 (0.14–2.20) 0.53 (0.17–1.65) 1.00 0.90 (0.55–1.48) 0.77 (0.42–1.41) 1.43 (0.59–3.46)
CVDd
No. of events 3 4 7 852 32 23 9
Incidence rateb 34.0 29.3 31.1 55.8 54.9 48.8 80.9
Age- and sex-adjusted HR (95% CI) 0.71 (0.23–2.20) 0.58 (0.22–1.56) 0.63 (0.30–1.33) 1.00 1.06 (0.74–1.51) 0.94 (0.62–1.43) 1.56 (0.81–3.01)
Multivariate adjusted HR (95% CI)c 0.66 (0.21–2.06) 0.62 (0.23–1.66) 0.64 (0.30–1.34) 1.00 1.00 (0.71–1.43) 0.89 (0.59–1.35) 1.48 (0.78–2.87)
Coronary heart diseasee
No. of events 3 3 6 564 15 11 4
Incidence rateb 34.0 21.7 26.5 35.9 24.6 22.5 33.0
Age- and sex-adjusted HR (95% CI) 1.12 (0.36–3.48) 0.67 (0.22–2.09) 0.84 (0.37–1.88) 1.00 0.75 (0.45–1.25) 0.68 (0.38–1.24) 1.00 (0.38–2.68)
Multivariate adjusted HR (95% CI)c 1.10 (0.35–3.44) 0.72 (0.23–2.25) 0.87 (0.39–1.96) 1.00 0.70 (0.42–1.18) 0.66 (0.36–1.19) 0.89 (0.33–2.38)
The euthyroidism group was used as the reference group.
a P  0.05 for comparison with the euthyroidism group.
b Per 1000 person-years.
c Adjusted for age, sex, education, history of CVD, diabetes, BMI, smoking status, systolic blood pressure, LDL cholesterol, creatinine, and -
blocker and antiarrhythmic use.
d CVD defined as fatal and nonfatal myocardial infarction or stroke, coronary artery bypass graft, percutaneous transluminal coronary angioplasty,
or peripheral arterial surgery or angioplasty.
e Coronary heart disease defined as fatal and nonfatal myocardial infarction.
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from a nonvascular cause, one developed atrial fibrilla-
tion, 16 (8%) developed overt hypothyroidism, and 60
(30%) normalized both TSH and free T4 (Supplemental
Fig. 1). For heart failure hospitalization, point estimates of
persistent subclinical hyperthyroidism compared with
persistent euthyroidism were above two, but the associa-
tion was not statistically significant (age- and sex-adjusted
HR  2.29, 95% CI  0.73–7.21, Table 4). Persistent
subclinical hypothyroidism with TSH above 10 mIU/liter
remained associated with heart failure hospitalization
compared with persistent euthyroidism with an age- and
sex-adjusted HR of 4.99 (95% CI  1.59–15.67, P 
0.006) and multivariate adjusted HR of 3.84 (95% CI 
1.20–12.29, P  0.023) (Table 4).
Sensitivity analysis
The exclusion of 161 participants with thyroid replace-
ment therapy yielded similar estimates for the association
between subclinical hyperthyroidism (TSH 0.45 mIU/
liter) and heart failure hospitalization, with a multivariate
adjusted HR of 2.45 (95% CI  1.00–6.01, P  0.05)
compared with euthyroidism. Similarly, after exclusion of
thyroid replacement therapy, the asso-
ciation between subclinical hypothy-
roidism defined as TSH levels above 10
mIU/liter and incident heart failure per-
sisted in both the age- and sex-adjusted
model (HR  3.87, 95% CI  1.24–
12.1, P  0.02) and the multivariate
adjusted model (HR  3.25, 95% CI 
1.03–10.2, P  0.045).
Discussion
In this large cohort of older people aged
70–82 yr old and at high risk of CVD,
subclinical hyperthyroidism was in-
dependently associated with heart
failure as estimated with hospital ad-
missions. Only subclinical hypothy-
roidism at a threshold of TSH above
10 mIU/liter was associated with in-
cident heart failure. The heart failure
risk associated with low TSH or very
high TSH values was maintained among
those with persistent thyroid dysfunc-
tion at 6 months. There was no strong
evidence of an association between
subclinical thyroid dysfunction and
atrial fibrillation or cardiovascular
events and mortality, although TSH
below 0.1 mIU/liter or above 10 mIU/
liter seemed to confer a higher risk.
In a population-based study of older people, the Car-
diovascular Health Study, no association was found be-
tween subclinical hyperthyroidism and heart failure
(HR  0.94, 95% CI  0.48–1.83) (11). The prevalence
of subclinical hyperthyroidism in that study (1.4%) was
similar to ours but lower than the 6% previously reported
in older people elsewhere (17). The Cardiovascular Health
Study population was at lower CVD risk than our study
population with lower prevalence of cardiovascular risk
factors, such as age (72.6 yr in the Cardiovascular Health
Study vs. 75.3 yr in PROSPER), current smoking (10.7 vs.
27.2%), hypertension (40.2 vs. 61.6%), or previous evi-
dence of CVD (19.6 vs. 44.2%). We also found a lower
BMI in participants with subclinical hyperthyroidism
compared with the euthyroidism group, as might be ex-
pected (18). There are a number of mechanisms by which
subclinical hyperthyroidism might influence cardiac out-
put and increase the incidence of heart failure, including
increased heart rate (19, 20), higher left ventricular mass,
and impaired diastolic function with delayed relaxation
(19), which in turn could cause or exacerbate heart failure.
FIG. 2. Stratified analysis for the association of subclinical hyperthyroidism with the risk of
heart failure hospitalization. The size of each square is proportional to the inverse variance of
the HR. Horizontal lines represent 95% CI. HR are adjusted for age and sex.
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Unlike the Cardiovascular Health Study, our study was
not designed to evaluate cardiac dysfunction with longi-
tudinal echocardiography, and we were not able to assess
cardiac changes or differentiate between systolic and di-
astolic dysfunction. Indeed, there may be a reverse causal
mechanism as there is limited evidence that cardiac resyn-
chronization therapy may improve free T4 and free T3
levels (21). Thus, we cannot exclude the possibility that
worsening cardiac function (leading to clinical heart fail-
ure) may impact on thyroid function. -Blockers have
been proposed as first-line agents in patient with overt
hyperthyroidism to reduce symptoms, because heart rate
might be in the causal pathway (8). In our subgroup anal-
ysis among adults using -blockers, the number of events
was too low to interpret with confidence point estimates.
Thus, the potential effect of heart rate reduction to prevent
incident heart failure in subclinical hyperthyroidism
should be evaluated in a formal clinical trial.





























No. of events 3 1 4 250 10 8 2
Incidence ratea 33.9 7.0 17.3 15.4 16.0 16.0 16.0
Age- and sex-adjusted HR (95% CI) 2.79 (0.89–8.74) 0.52 (0.07–3.71) 1.33 (0.50–3.59) 1.00 1.16 (0.62–2.19) 1.16 (0.57–2.35) 1.17 (0.29–4.70)
Multivariate adjusted HR (95% CI)b 2.90 (0.92–9.13) 0.66 (0.09–4.73) 1.57 (0.58–4.24) 1.00 1.05 (0.56–1.99) 1.13 (0.55–2.28) 0.84 (0.21–3.41)
Total mortality
No. of events 5 2 7 517 23 20 3
Incidence ratea 56.5 14.0 30.3 31.8 36.7 39.9 24.0
Age- and sex-adjusted HR (95% CI) 2.11 (0.87–5.09) 0.48 (0.12–1.94) 1.07 (0.51–2.27) 1.00 1.25 (0.82–1.90) 1.36 (0.87–2.13) 0.82 (0.26–2.55)
Multivariate adjusted HR (95% CI)b 2.01 (0.83–4.89) 0.57 (0.14–2.30) 1.17 (0.55–2.47) 1.00 1.23 (0.81–1.86) 1.39 (0.89–2.17) 0.69 (0.22–2.16)
The euthyroidism group was used as the reference group.
a Per 1000 person-years.
b Adjusted for age, sex, education, history of CVD, diabetes, BMI, smoking status, systolic blood pressure, LDL cholesterol, creatinine, and -
blocker and antiarrhythmic use.





























No. of events 1 2 3 147 5 2 3
Incidence rateb 22.0 24.4 23.6 12.0 16.8 8.3 52.6a
Age- and sex-adjusted HR (95% CI) 2.29 (0.32–16.43) 2.29 (0.57–9.29) 2.29 (0.73–7.21) 1.00 1.46 (0.60–3.56) 0.71 (0.18–2.86) 4.99a (1.59–15.67)
Multivariate adjusted HR (95% CI)c 2.22 (0.31–16.08) 2.62 (0.64–10.67) 2.47 (0.78–7.83) 1.00 1.35 (0.55–3.31) 0.69 (0.17–2.79) 3.84a (1.20–12.29)
Atrial fibrillation
No. of events 1 2 3 395 8 5 3
Incidence rateb 23.3 24.6 24.1 33.0 26.9 20.8 53.0
Age- and sex-adjusted HR (95% CI) 0.84 (0.12–5.98) 0.85 (0.21–3.42) 0.85 (0.27–2.64) 1.00 0.86 (0.43–1.73) 0.66 (0.27–1.59) 1.76 (0.56–5.48)
Multivariate adjusted HR (95% CI)c 0.96 (0.13–6.84) 0.89 (0.22–3.57) 0.91 (0.29–2.84) 1.00 0.82 (0.41–1.65) 0.63 (0.26–1.52) 1.68 (0.54–5.26)
CVDd
No. of events 1 4 5 635 15 10 5
Incidence rateb 22.0 51.9 40.8 54.9 53.4 43.9 93.5
Age- and sex-adjusted HR (95% CI) 0.46 (0.07–3.29) 1.10 (0.41–2.94) 0.86 (0.36–2.08) 1.00 1.01 (0.61–1.69) 0.82 (0.44–1.54) 1.86 (0.77–4.49)
Multivariate adjusted HR (95% CI)c 0.40 (0.06–2.84) 1.12 (0.42–3.02) 0.82 (0.34–1.99) 1.00 0.91 (0.56–1.53) 0.75 (0.40–1.40) 1.62 (0.67–3.93)
Total mortality
No. of events 2 2 4 386 9 7 2
Incidence rateb 44.0 24.0 31.1 31.2 29.8 28.7 34.1
Age- and sex-adjusted HR (95% CI) 1.72 (0.43–6.92) 0.90 (0.22–3.63) 1.18 (0.44–3.18) 1.00 1.02 (0.53–1.98) 0.97 (0.46–2.06) 1.23 (0.31–4.93)
Multivariate adjusted HR (95% CI)c 1.46 (0.36–5.92) 1.16 (0.29–4.69) 1.30 (0.48–3.49) 1.00 0.97 (0.50–1.88) 0.96 (0.46–2.04) 0.97 (0.24–3.94)
The euthyroidism group was used as the reference group.
a P  0.05 for comparison with the euthyroidism group.
b Per 1000 person-years.
c Adjusted for age, sex, education, history of CVD, diabetes, BMI, smoking status, systolic blood pressure, LDL cholesterol, creatinine, and -
blocker and antiarrhythmic use.
d CVD defined as fatal and nonfatal myocardial infarction or stroke, coronary artery bypass graft, percutaneous transluminal coronary angioplasty,
or peripheral arterial surgery or angioplasty.
858 Nanchen et al. Subclinical Thyroid Dysfunction J Clin Endocrinol Metab, March 2012, 97(3):852–861
The association between subclinical hypothyroidism
and cardiovascular outcomes and mortality has been dem-
onstrated mainly in adults with TSH values above 10 mIU/
liter (3). Similar to our results, two previous studies re-
ported an increased risk of incident heart failure in older
adults particularly when TSH levels were above 10 mIU/
liter (11, 22). However, the possible fluctuation of thyroid
dysfunction over time might have contributed to the main
negative findings of previous studies, because in many in-
dividuals, TSH normalizes over time (from 15–65% over
follow-up periods going from 1–6 yr) (23, 24). Very few
cohort studies have repeated TSH measurement within 3
or 6 months to exclude transient dysfunction (5, 17). In
our study, we could demonstrate that the persistence of
elevated TSH values above 10 mIU/liter over a 6-month
period were still associated with incident heart failure hos-
pitalizations and might even increase this risk, although
the number of events was low.
Atrial fibrillation, a well-known consequence of overt
hyperthyroidism (8, 25), might also predispose to the de-
velopment of heart failure. However, we did not find any
association between subclinical thyroid dysfunction and
incident atrial fibrillation in our study, in contrast to pre-
vious reports (26–28). Thus, it seems unlikely that the
increased incidence rate of heart failure that we have ob-
served with subclinical hyperthyroidism and hypothy-
roidism was mediated by atrial fibrillation. The lack of
effect on atrial fibrillation might be due to study selection
criteria. In our population at high risk for vascular disease,
subclinical thyroid dysfunction might not be a major fac-
tor in causing atrial fibrillation. In subgroup analyses, we
found no association with atrial fibrillation in older adults
with suppressed TSH below 0.1 mIU/liter. However, par-
ticipants with free T4 concentrations above 18 pmol/liter
were excluded in our study (defined as overt thyrotoxico-
sis). Previous studies showing an association with atrial
fibrillation have included participants with higher free T4
concentrations, such as 20 pmol/liter (27) or 22 pmol/liter
(10). These results might indicate that free T4 concentra-
tions may be more strongly associated with atrial fibril-
lation than TSH concentrations, as previously reported
elsewhere (27).
Furthermore, we did not find an association between
suppressed TSH below 0.1 mIU/liter or high TSH above
10 mIU/liter and cardiovascular events or mortality only
in subgroups of older adults not using pravastatin over a
3.2-yr follow-up period. Previous studies with longer fol-
low-up (10, 17, 29) or very old adults (6) have shown
conflicting results, and meta-analyses found a modestly
increased risk for cardiovascular mortality associated
with subclinical hyperthyroidism (2, 30) and subclinical
hypothyroidism (3). For subclinical hyperthyroidism, the
highest cardiovascular mortality rates were found in stud-
ies with a convenience sample of hospitalized patients (5,
31), and a meta-analysis that included the two latter stud-
ies found a significant association between subclinical hy-
perthyroidism and all-cause mortality (32). In older adults
or those with comorbidities, experts recommend treat-
ment for TSH values lower than 0.1 mIU/liter and normal
free T4 (1). Our large study provides further evidence that
subclinical thyroid dysfunction defined as suppressed
TSH or high TSH values might be associated with first or
recurrent cardiovascular events and cardiovascular mor-
tality in ambulatory older adults at high-risk of CVD.
Our study has several limitations. Like most previous
large cohort studies (6, 10, 29, 33), free T3 was not mea-
sured, and thyroid dysfunction was diagnosed with TSH
and free T4 only. Free T3 would have been important to
diagnose older adults with overt hyperthyroidism and T3
toxicosis, because they would have greater increase in free
T3 than free T4. However, according to the protocol of the
PROSPER study (13), participants with symptoms and
signs of overt hyperthyroidism, including atrial fibrilla-
tion, shortnessofbreath,heart failure, hyperglycemia, and
thyroid cancer were excluded at baseline. Moreover, we
excluded patients with antithyroid drug therapy, which
has been associated with discordance between free T3 and
T4 levels (34). We additionally excluded participants with
current use of amiodarone at baseline, but we were not
able to assess previous use, because amiodarone can have
long-lasting effects. Five older adults with subclinical hy-
perthyroidism and 34 (15%) with subclinical hypothy-
roidism used thyroid hormone. To examine the risks of
endogenous subclinical thyroid dysfunction, we did a sen-
sitivity analysis excluding those using thyroid hormone
and found similar estimates. We were not able to adjust
our estimates for NYHA classification, and residual con-
founding might have occurred. However, participants with
existing heart failure (NYHA class III and IV) were excluded
at baseline according to the study protocol (13). Finally, the
study population was derived from a clinical trial among
older people with cardiovascular risk factors or previous
CVD, which might limit the external validity of our findings.
However, with the rapid aging of the population, the prev-
alence of chronic cardiovascular conditions due to earlier
CVD will increase. Consequently, our large cohort of high-
risk older people with well-defined and adjudicated cardio-
vascular events can be viewed as a major opportunity to
understand the future burden of aging disease.
In older adults at high risk of vascular disease, subclin-
ical hyperthyroidism and subclinical hypothyroidism with
TSH values above 10 mIU/liter were associated with in-
creased incidence rate of heart failure hospitalization over
a period of 3 yr. This effect was not mediated by the oc-
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currence of atrial fibrillation. Heart failure is associated
with a large morbidity and mortality in the aging popu-
lation, and TSH is a potentially modifiable risk factor.
Treatment of subclinical hyperthyroidism and subclinical
hypothyroidism to prevent heart failure and cardiovascu-
lar disease in older people should be evaluated in large
randomized clinical trials. Pending such future studies,
current recommendations to consider therapy if TSH is
above 10 mIU/liter or less than 0.1 mIU/liter seems
appropriate.
Acknowledgments
Address all correspondence and requests for reprints to: David
Nanchen, University of Lausanne, Department of Ambulatory
Care and Community Medicine, Rue du Bugnon 44, CH-1011
Lausanne, Switzerland. E-mail: david.nanchen@chuv.ch or
d.nanchen@lumc.nl.
This research was supported by The Netherlands Genomics
Initiative/Netherlands Organization for Scientific Research
(NGI/NWO; 05040202 and 050-060-810 Netherlands Consor-
tium for Healthy Aging to R.G.J.W. and A.J.M.d.C.). This re-
search was also supported by Swiss National Science Foundation
grants (PBLAP3-132943 to D.N. and SNSF 320030-138267 to
N.R.), the SICPA Foundation and the Société Académique Vau-
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